How big is Chromadex Corp.?

As of Jun 18, Chromadex Corp. has a market capitalization of 1,093.32 million, with net sales of 107.92 million and a net profit of 14.11 million for the latest four quarters. The balance sheet as of December 2024 shows shareholder's funds of 46.09 million and total assets of 68.28 million.

As of Jun 18, Chromadex Corp. has a market capitalization of 1,093.32 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 107.92 million and a net profit of 14.11 million for the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024.<BR><BR>As of December 2024, the balance sheet shows shareholder's funds of 46.09 million and total assets of 68.28 million.

What does Chromadex Corp. do?

Chromadex Corporation is a nutraceutical company in the Pharmaceuticals & Biotechnology industry, focusing on research and quality-control products for the natural products sector. As of March 2025, it reported net sales of $30 million and a net profit of $5 million, with a market cap of approximately $1.09 billion.

Overview: <BR>Chromadex Corporation is an integrated nutraceutical company operating in the Pharmaceuticals & Biotechnology industry, focusing on research and quality-control products and services for the natural products sector.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 30 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 5 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,093.32 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 63.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.99 <BR>Return on Equity: 29.28% <BR>Price to Book: 19.75 <BR><BR>Contact Details: <BR>Address: 10900 Wilshire Blvd Ste 600, LOS ANGELES CA: 90024-6534 <BR>Tel: ['1 310 3886706', '1 949 4190288'] <BR>Fax: 1 302 6583694 <BR>Website: https://chromadex.com/default.aspx

Should I buy, sell or hold Chromadex Corp.?

Who are in the management team of Chromadex Corp.?

As of March 2022, the management team of Chromadex Corp. includes Frank Jaksch (Executive Chairman), Robert Fried (CEO), Kurt Gustafson (Lead Independent Director), and several Independent Directors: Jeffrey Baxter, Stephen Block, Tony Lau, and Steven Rubin. They oversee the company's operations and strategic direction.

As of March 2022, the management team of Chromadex Corp. includes the following individuals:<BR><BR>- Mr. Frank Jaksch, Executive Chairman of the Board<BR>- Mr. Robert Fried, Chief Executive Officer and Director<BR>- Mr. Kurt Gustafson, Lead Independent Director<BR>- Mr. Jeffrey Baxter, Independent Director<BR>- Mr. Stephen Block, Independent Director<BR>- Mr. Tony Lau, Independent Director<BR>- Mr. Steven Rubin, Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Is Chromadex Corp. technically bullish or bearish?

As of July 14, 2025, Chromadex Corp. shows a mildly bullish trend with mixed technical indicators, having outperformed the S&P 500 with a return of 185.63% compared to 17.14%.

As of 14 July 2025, the technical trend for Chromadex Corp. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are both mildly bearish, while the monthly MACD, Bollinger Bands, and OBV are bullish. The daily moving averages indicate a bullish stance. Overall, the mixed signals suggest a mildly bullish outlook. <BR><BR>In terms of performance, Chromadex has significantly outperformed the S&P 500 over the past year with a return of 185.63% compared to the S&P 500's 17.14%.

Is Chromadex Corp. overvalued or undervalued?

As of October 17, 2025, Chromadex Corp. is considered undervalued with an attractive PEG ratio of 0.07 and strong long-term performance, despite a higher P/E ratio compared to some peers and recent short-term underperformance.

As of 17 October 2025, the valuation grade for Chromadex Corp. has moved from expensive to attractive, indicating a shift in perception towards the stock's value. The company appears to be undervalued, particularly given its impressive PEG ratio of 0.07, which suggests significant growth potential relative to its price, alongside a high ROCE of 1532.90% and a ROE of 29.28%. <BR><BR>In comparison to peers, Chromadex Corp. has a P/E ratio of 63, which is notably higher than LifeVantage Corp.'s attractive P/E of 14.81, yet lower than USANA Health Sciences' expensive P/E of 16.23. Despite recent short-term underperformance, with a 1-month return of -23.88% compared to the S&P 500's 0.96%, the company has shown remarkable long-term performance, with a 1-year return of 113.08% versus the S&P 500's 14.08%. This long-term outperformance reinforces the attractiveness of Chromadex Corp.'s current valuation.